ANÁLISIS DE COSTO-EFECTIVIDAD EN EL TRATAMIENTO ANALGÉSICO PARA DOLOR POST-OPERATORIO
. PO pain manifests in a moderate or intense manner in 40% to 60% of cases for more than 50% of the time (2) . Its somatic and psychic expression may be directly or indirectly associated with increased morbidity and mortality, with consequent social and economic repercussions. Thus, over the last decades this organic manifestation has gained the dimensions of a world public health problem (3) .
In developed countries, the interest in the economic aspects of analgesia applied during the PO period is recent and has been concentrated on highcost treatments, especially in view of the use of new technologies in the management of discomfort (4) (5) (6) . A single study is available din Brazil in which the author compared to costs and outcomes of different analgesic methods in patients submitted to different types of surgery (7) .
However, although scarce, some studies of CEA were found in which the authors compared the PCA method to the classical method of intramuscular morphine administration in patients submitted to gynaecological surgery (5) . Authors analyzed analgesic therapy in patients with fractured limbs by comparing ketorolac and morphine (8) . for the use of more resources, we must say that the world literature presents a large gap with respect to this topic (9) .
In view of the above considerations and of a scenario in which the practice and the technical decisions of health professionals are increasingly tied to economic restrictions, the objective of the present study was to carry out a cost-effectiveness analysis of the analgesic schemes used for surgical patients on the first PO day (1stPO).
SAMPLE AND METHODS
The Paulo were consulted (11) and the Departments of Human Resources of various hospitals were contacted in order to estimate the costs of the analgesic schemes. The analgesic schemes were submitted to the CEA and the results were expressed as a quotient in which the numerator was the cost of the therapy estimated for 100 patients and the denominator was the effectiveness estimated according to the above criteria. The efficiency of one analgesic scheme in relation to the other was compared by applying mean and incremental cost-effectiveness analysis.
F o r t h e c o s t e s t i m a t e s o f t h e r
We used sensitivity analysis and modified the effectiveness of the analgesic schemes on the basis of the pain-expressing behavior of the patients under study.
RESULTS
The compositions of the therapeutic schemes (Table 1) . of care (12) . Thus, considering that the objective of analgesic therapy during the PO period is to control pain and that the CEA of therapeutic schemes is preceded by the identification of the outcome on the basis of which relative effectiveness should be measured, the criteria was established based on the real parameters available at the site of investigation, exactly because this was a study focusing on effectiveness and not on efficacy.
The CEA was expressed by the costeffectiveness relation, i.e., by the benefit conferred by the therapeutic strategy used under routine clinical practice conditions (9) (10) . The CEA showed that the (C) scheme expressed the worst cost-effectiveness ratio, with a cost of $592,98 per patient without a breakthrough pain episode. The (E) scheme presented the lowest cost per effectiveness unit, which represents the best cost-effectiveness relationship, i.e., $ 192,76
per patient with no breakthrough pain episode. These results confirm literature recommendations which state that multimodal schemes are more effective for the treatment of PO pain (2, 8, (13) (14) . Table 4 shows that, according to scenario 1, the (D) and (E) schemes presented similar effectiveness (43.0%), while the (C) scheme was the worst (33.0%). It can also be seen that the recalculated mean cost-effectiveness of (E) ($ Original scenario -Nº of patients who did not present breakthrough pain episodes/total Nº of patients Scenario 1 -Nº of patients who presented a maximum of 1 breakthrough pain episode/total Nº of patients Scenario 2 -Nº of patients who presented 3 or more breakthrough pain episodes/total total Nº of patients
DISCUSSION
The emphasis on cost containment and on improved efficiency of the health system has created the explicit need to quantify and justify the costs and benefits related to specific therapies so that more rational therapeutic decisions may be made. Thus, a worldwide increase in assessment studies has been However, the study has limitations that should be pointed out so that others will be able to reduce or remedy them. This was a retrospective investigation that, even though it used information from the medical records, which indeed was the expression of the events 
